|
|
Epigenomics and Roche Diagnostics extend R&D collaboration agreement
 |
 |
| Date: Friday, 30.09.2005 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced an extension to its existing agreement with Roche Diagnostics, a world leader in molecular diagnostics. The R&D part of the collaboration, which covers the development of five cancer diagnostic tests, has been extended for a minimum of 6 months, with the option to prolong and potentially expand for another 18 months. Financial terms were not disclosed.
"Shortly before announcing final validation data for our two lead products, we extended our R&D partnership. This gives both parties the flexibility to act based upon the final outcomes of these programs. I expect further newsflow from our alliance shortly after the release of each program’s final clinical performance data" noted Alex Olek, CEO of Epigenomics.
Epigenomics’ collaboration with Roche Diagnostics, involves the development of five cancer diagnostics; one of each to screen for colon, prostate and breast cancers; a test to determine how aggressively prostate cancer is growing; and a pharmacodiagnostic test to predict the probability of relapse in breast cancer patients undergoing treatment with tamoxifen.
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics’ tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.
# # #
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. |
|
| back |
|
top of the page
|
